Synonym
Osalmid; Auxobil; Oksafenamid; NSC 93960; NSC-93960; NSC93960; Salmidochol; PHPS; Saryuurin;
IUPAC/Chemical Name
2-hydroxy-N-(4-hydroxyphenyl)benzamide
InChi Key
LGCMKPRGGJRYGM-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H11NO3/c15-10-7-5-9(6-8-10)14-13(17)11-3-1-2-4-12(11)16/h1-8,15-16H,(H,14,17)
SMILES Code
O=C(NC1=CC=C(O)C=C1)C2=CC=CC=C2O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Osalmid is a potential RRM2-targeting compound.
In vitro activity:
Osalmid was shown to be 10-fold more active in inhibiting RR activity than hydroxyurea, and significantly inhibited HBV DNA and cccDNA synthesis in HepG2.2.15 cells. In contrast, hydroxyurea and the RR large subunit (RRM1)-inhibitory drug gemcitabine showed little selective activity against HBV replication. In addition, osalmid also was shown to possess potent activity against a 3TC-resistant HBV strain, suggesting utility in treating drug-resistant HBV infections.
Reference: Biochem Pharmacol. 2016 Mar 1;103:118-28. https://pubmed.ncbi.nlm.nih.gov/26774458/
In vivo activity:
A xenograft mouse model of EC was used to investigate the potential synergistic effects of Osalmid and IR in vivo. Treatment with Osalmid and IR significantly suppressed tumor growth in xenograft EC models without additional toxicity to the hematologic system and internal organs.
Reference: Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1368-1379. https://pubmed.ncbi.nlm.nih.gov/32763454/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
72.5 |
316.27 |
| Ethanol |
45.0 |
196.31 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
229.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Zhou J, Zhang M, Zhang Y, Shi X, Liu L, Yao R. Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments. Front Genet. 2021 Sep 10;12:722132. doi: 10.3389/fgene.2021.722132. PMID: 34567073; PMCID: PMC8461066.
2. Liu X, Xu Z, Hou C, Wang M, Chen X, Lin Q, Song R, Lou M, Zhu L, Qiu Y, Chen Z, Yang C, Zhu W, Shao J. Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol. 2016 Mar 1;103:118-28. doi: 10.1016/j.bcp.2016.01.003. Epub 2016 Jan 13. PMID: 26774458.
3. Tang Q, Wu L, Xu M, Yan D, Shao J, Yan S. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1368-1379. doi: 10.1016/j.ijrobp.2020.07.2322. Epub 2020 Aug 4. PMID: 32763454.
In vitro protocol:
1. Zhou J, Zhang M, Zhang Y, Shi X, Liu L, Yao R. Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments. Front Genet. 2021 Sep 10;12:722132. doi: 10.3389/fgene.2021.722132. PMID: 34567073; PMCID: PMC8461066.
2. Liu X, Xu Z, Hou C, Wang M, Chen X, Lin Q, Song R, Lou M, Zhu L, Qiu Y, Chen Z, Yang C, Zhu W, Shao J. Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol. 2016 Mar 1;103:118-28. doi: 10.1016/j.bcp.2016.01.003. Epub 2016 Jan 13. PMID: 26774458.
In vivo protocol:
1. Tang Q, Wu L, Xu M, Yan D, Shao J, Yan S. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1368-1379. doi: 10.1016/j.ijrobp.2020.07.2322. Epub 2020 Aug 4. PMID: 32763454.
1: Liu X, Xu Z, Hou C, Wang M, Chen X, Lin Q, Song R, Lou M, Zhu L, Qiu Y, Chen Z, Yang C, Zhu W, Shao J. Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol. 2016 Mar 1;103:118-28. doi: 10.1016/j.bcp.2016.01.003. Epub 2016 Jan 13. PubMed PMID: 26774458.
2: Hu F, An J, Li W, Zhang Z, Chen W, Wang C, Wang Z. UPLC-MS/MS determination and gender-related pharmacokinetic study of five active ingredients in rat plasma after oral administration of Eucommia cortex extract. J Ethnopharmacol. 2015 Jul 1;169:145-55. doi: 10.1016/j.jep.2015.04.007. Epub 2015 Apr 22. PubMed PMID: 25910535.
3: Sadanaga T, Hikida K, Tameto K, Sugimoto K, Nakanishi M, Matsushima Y, Ohkura Y. Determination of osalmid in plasma by high-performance liquid chromatography. J Chromatogr. 1981 Apr 10;223(1):243-6. PubMed PMID: 7251772.
